v3.22.2.2
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows from Operating Activities    
Net loss $ (31,548,479) $ (21,791,941)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
In-process R&D impairment loss 3,500,000  
Depreciation and amortization 988,715 415,270
Amortization of intangible asset 666,875  
Noncash lease expense 127,681 78,697
Stock-based compensation 2,430,389 4,376,588
Change in fair value of common stock warrants (10,746) (2,808)
Change in fair value of contingent consideration (3,342,515) 406,000
Unrealized loss on investments 1,577,174 278,172
Increase (decrease) in cash arising from changes in assets and liabilities:    
Accounts receivable (5,843,564) 104,598
Prepaid expenses and other current assets 1,210,730 (1,029,581)
Contract receivables 24,526,231  
Income tax receivable 443,968  
Grant receivable (206,163) (870,032)
Inventory 5,844,000  
Other assets 12,493,539 (8,199,850)
Right-of-use assets (9,974,366)  
Accounts payable 2,354,279 14,766
Accrued expenses and other liabilities (3,512,090) 197,428
Other long-term liabilities (53,530) 14,268
Deferred tax liability (215,937)  
Deferred revenue 718,850 (603,717)
Deposits (33,064) (126,778)
Net Cash Provided by (Used In) Operating Activities 2,141,977 (26,738,920)
Cash Flows from Investing Activities    
Purchase of short-term investments (1,989,767) (66,665,908)
Sale of short-term investments 44,947,779 66,197,924
Purchase of property and equipment (19,271,087) (1,383,596)
Acquisition of Elusys Therapeutics, net of cash paid 2,719,898  
Payment of contingent consideration (22,784,571)  
Net Cash Provided By (Used In) Investing Activities 3,622,252 (1,851,580)
Cash Flows from Financing Activities    
Proceeds from the issuance of common stock   26,304,282
Proceeds from exercise of stock options   27,261
Stock issuance costs   (658,184)
Repayments on principal of finance lease (145,672) (121,503)
Net Cash (Used In) Provided by Financing Activities (145,672) 25,551,856
Effect of exchange rate changes on cash and cash equivalents (14,194) (10,834)
Net Increase (Decrease) in Cash and Cash Equivalents 5,604,363 (3,049,478)
Cash and Cash Equivalents - Beginning of Period 8,053,879 10,931,890
Cash and Cash Equivalents - End of Period 13,658,242 7,882,412
Supplemental Disclosure for Cash Flow Information:    
Right-of-use assets obtained on operating lease commencements 351,098 88,596
Right-of-use assets obtained on operating lease modifications   37,767
Right-of-use assets obtained on financing lease commencements 16,470,969 $ 408,677
Supplemental disclosure of non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable 1,233,232  
Contingent and deferred cash consideration related to Elusys acquisition $ 42,853,685  

Source

PDF HTML 10-Q Filing
ZIP XLS XBRL